In this context, siRNA-mediated gene silencing targets multiple cancer hallmarks, such as cell cycle progression (PLK-1, KSP), evasion of apoptosis (Survivin, Bcl-2), DNA repair (MGMT, RAD51), tumor microenvironment remodeling (CXCR4, nerve growth factor), and immune evasion (PD-L1), collectively enhancing the antitumor effect. Here, PLK1 is linked to neoplasm.